Track Janux Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Janux Therapeutics Inc. Common Stock JANX · Stock Open Janux Therapeutics Inc. Common Stock in new tab

11.37 USD
EPS
-1.59
P/B
0.76
ROE
-10.58
Beta
2.39
Target Price
33.14 USD
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-1.59
Book Value14.90
Price to Book0.76
Debt/Equity2.24
% Insiders1.262%
Growth
Revenue Growth-0.07%
Estimates
Forward P/E-4.46
Forward EPS-2.55
Target Mean Price33.14

DCF valuation

Model fair value for Janux Therapeutics Inc. Common Stock (JANX)
Result
Sign in to run the valuation for JANX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
14 analysts · consensus Strong buy · mean target 33.14 USD (low 15.00, high 60.00) · as of 16 Nov 2026
Low 15.00
Mean 33.14
High 60.00
Price 11.37
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Janux Therapeutics Inc. Common Stock Logo Janux Therapeutics Inc. Common Stock Analysis (JANX)

United States Health Care Official Website Stock

Is Janux Therapeutics Inc. Common Stock a good investment? Janux Therapeutics Inc. Common Stock (JANX) is currently trading at 11.37 USD. Market analysts have a consensus price target of 33.14 USD. This suggests a potential upside from current levels.

Earnings Schedule: Janux Therapeutics Inc. Common Stock is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -2.55.

Investor FAQ

Does Janux Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Janux Therapeutics Inc. Common Stock?

Janux Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -1.59.

Company Profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Exchange Ticker
NMS (United States) JANX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion